MNPR Stock News & Catalysts – Monopar Therapeutics

FEATURED

Monopar Presents Data Highlighting Residual Disease Burden in Treatment-Experienced Wilson Disease Patients and Long-Term Molybdenum Safety Data for ALXN1840 at AASLD – The Liver Meeting® 2026

New

WILMETTE, Ill., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for

Summary

Nov 9, 2026, 8:00 AM ·Globe Newswire

RECENT

Monopar to Present at AASLD – The Liver Meeting® 2026: Phase 3 FoCus Baseline Data and ALXN1840 Molybdenum Safety Data

WILMETTE, Ill., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for

Nov 2, 2026, 8:00 AM ·Globe Newswire

Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLD – The Liver Meeting® 2026

WILMETTE, Ill., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for

Aug 19, 2026, 8:00 AM ·Globe Newswire

Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

WILMETTE, Ill., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:MNPR), a clinical‐stage biopharmaceutical company developing innovative treatments for

Aug 12, 2026, 9:30 AM ·Globe Newswire

Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease

WILMETTE, Ill., July 22, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for

Jul 22, 2026, 8:00 AM ·Globe Newswire

Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team

WILMETTE, Ill., July 20, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for

Jul 20, 2026, 8:00 AM ·Globe Newswire

Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease

WILMETTE, Ill., June 30, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for

Jun 30, 2026, 8:00 AM ·Globe Newswire

Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease

WILMETTE, Ill., June 26, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for

Jun 26, 2026, 4:05 PM ·Globe Newswire

Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026

WILMETTE, Ill., June 01, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with

Jun 1, 2026, 7:00 AM ·Globe Newswire

Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease

WILMETTE, Ill., May 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet

May 19, 2026, 5:33 PM ·Globe Newswire

Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

WILMETTE, Ill., May 14, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:MNPR), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet

May 14, 2026, 2:00 PM ·Globe Newswire

Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026

WILMETTE, Ill., April 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with

Apr 19, 2026, 7:00 PM ·Globe Newswire

Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update

WILMETTE, Ill., March 27, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar," the "Company," "we") (NASDAQ:MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with

Mar 27, 2026, 1:00 PM ·Globe Newswire

Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer

WILMETTE, Ill., March 02, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR) ("Monopar" or the "Company"), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with

Mar 2, 2026, 8:00 AM ·Globe Newswire

Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments

WILMETTE, Ill., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:MNPR), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with

Nov 13, 2025, 8:00 AM ·Globe Newswire

Monopar Therapeutics Inc. MNPR · News